VERTEX PHARMACEUTICALS INC / MA
VRTX evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Market Cap:
- $130.36B
- Lead Asset:
- alyftrek (Approved)
What it means
What to watch
Prepared research question
What matters most for VRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VRTX
Vertex Pharmaceuticals is a biotech company with a dominant cystic fibrosis franchise, expanding into kidney disease, rare endocrinology, and pain through pipeline assets and the $10B Crinetics acquisition.
Key risk: CF franchise patent cliff
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 64 clinical trials · 7 catalysts · 9 FDA decisions for VERTEX PHARMACEUTICALS INC / MA.
Vertex Pharmaceuticals is a biotech company with a dominant cystic fibrosis franchise, expanding into kidney disease, rare endocrinology, and pain through pipeline assets and the $10B Crinetics acquisition.
- Cash & equivalents of $6,143.5M as of 2026-06-30 [sec]
- Total revenue of $3,333.9M and net income of $1,099.8M as of 2026-06-30 [sec]
- Completed $10 billion acquisition of Crinetics Pharmaceuticals on September 1, 2026, adding PALSONIFY and atumelnant [news]
- Positive Phase II data for inaxaplin in kidney disease, with AMPLITUDE interim results targeted in early 2027 [news]
- Full-year 2026 revenue guidance raised to $13.10–$13.20 billion [news]
What works
- Predictable CF cash flows and a wide, durable moat in cystic fibrosis [news]
- Expanding pipeline beyond CF with kidney disease candidates povetacicept and inaxaplin [news]
- Completed $10B Crinetics acquisition adds rare endocrine drugs with combined peak revenue potential >$5B [news]
- Raised 2026 revenue guidance to $13.10–$13.20 billion after strong Q2 results [news]
What to weigh
- Heavy reliance on cystic fibrosis franchise for current revenue, with patent expirations beginning in 2030 [catalyst]
- Kidney disease pipeline is still in clinical stages; pivotal data (AMPLITUDE interim) not expected until early 2027 [news]
- Large $10B acquisition cost for Crinetics adds integration risk and financial commitment [news]
From the filings
Quoted directly from source documents.
Completion of Crinetics acquisition
“Vertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.”
News · September 1, 2026
Positive Phase II data for inaxaplin
“VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.”
News · September 23, 2026
Catalyst timeline
- 2027-07-31 · Phase3_Start: A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype — Initiation of a Phase 3 trial for exa-cel in a specific sickle cell genotype, expanding the cell therapy's potential market.
- 2030-12-11 · Patent_Expiry · IVACAFTOR; LUMACAFTOR — Patent_Expiry: NDA206038 — First patent expiry for key CF drugs, potentially opening the door to generic competition.
- 2033-02-27 · Patent_Expiry · IVACAFTOR — Patent_Expiry: NDA207925 — Additional patent expiry for ivacaftor, further exposing the CF franchise.
- 2035-04-14 · Patent_Expiry · IVACAFTOR; IVACAFTOR, TEZACAFTOR — Patent_Expiry: NDA210491 — Patent expiry covering multiple CF combination products.
- 2038-07-17 · Patent_Expiry · ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR — Patent_Expiry: NDA217660 — Expiry of patents for elexacaftor/tezacaftor/ivacaftor combination therapy.
- 2040-12-04 · Patent_Expiry · SUZETRIGINE — Patent_Expiry: NDA219209 — Patent expiry for suzetrigine, a pain drug in Vertex's pipeline.
- 2043-01-10 · Patent_Expiry · DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM — Patent_Expiry: NDA218730 — Patent expiry for deutivacaftor/tezacaftor/vanzacaftor calcium combination.
Risks & what to watch (3)›
Key risks
- CF franchise patent cliff — First patent expiry for IVACAFTOR/LUMACAFTOR in 2030, with several more through 2043 [catalyst]
- Kidney pipeline still unproven — Key kidney drug inaxaplin only in Phase II; pivotal interim data not until early 2027 [news]
- Integration of $10B acquisition — Crinetics acquisition adds rare endocrine assets but carries significant financial and operational integration risk [news]
What to watch
- AMPLITUDE interim results for inaxaplin in kidney disease, expected early 2027 [news]
- Commercial ramp of Crinetics-acquired drugs PALSONIFY and atumelnant [news]
- Full-year 2026 revenue achievement against raised guidance of $13.10–$13.20 billion [news]
- Phase 3 start for exa-cel in severe sickle cell disease (βS/βC genotype) on 2027-07-31 [catalyst]
Sources: Catalysts · News · Generated October 4, 2026 · How we verify sources →
Run VERTEX PHARMACEUTICALS INC / MA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VERTEX PHARMACEUTICALS INC / MA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.35 · 1% dilution
Lead: Approved
8 candidates
7 upcoming, next in ~290d
0 buys · 14 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 1.9%
- Days to cover
- 3.7
- Shares short
- 4,172,829
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VRTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for VERTEX PHARMACEUTICALS INC / MA?
Vertex Pharmaceuticals is a biotech company with a dominant cystic fibrosis franchise, expanding into kidney disease, rare endocrinology, and pain through pipeline assets and the $10B Crinetics acquisition.
What is VERTEX PHARMACEUTICALS INC / MA's lead drug candidate?
VERTEX PHARMACEUTICALS INC / MA's most advanced tracked candidate is alyftrek (Approved).
What is VERTEX PHARMACEUTICALS INC / MA's next catalyst?
VERTEX PHARMACEUTICALS INC / MA's next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype" — expected July 31, 2027.
Who is the CEO of VERTEX PHARMACEUTICALS INC / MA?
Dr. Reshma Kewalramani FASN, M.D. is the chief executive officer of VERTEX PHARMACEUTICALS INC / MA (VRTX).
Where is VERTEX PHARMACEUTICALS INC / MA headquartered?
VERTEX PHARMACEUTICALS INC / MA (VRTX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.